Biomarkers for severe eosinophilic asthma.

Biomarkers for severe eosinophilic asthma.

The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or...

Bibliografske podrobnosti
Main Authors:	Yancey, S, Keene, O, Albers, F, Ortega, H, Bates, S, Bleecker, E, Pavord, I
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2017

Podobne knjige/članki

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
od: Yancey, S, et al.
Izdano: (2016)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
od: Ortega, H, et al.
Izdano: (2016)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
od: Gunsoy, N, et al.
Izdano: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
od: Shrimanker, R, et al.
Izdano: (2018)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
od: Pavord, I, et al.
Izdano: (2012)

Mepolizumab treatment in patients with severe eosinophilic asthma.
od: Ortega, H, et al.
Izdano: (2014)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
od: Bel, E, et al.
Izdano: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
od: Steven W. Yancey, et al.
Izdano: (2019-09-01)

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
od: Shrimanker, R, et al.
Izdano: (2019)

Glucocorticoids and mepolizumab in eosinophilic asthma.
od: Bel, E, et al.
Izdano: (2014)

Mepolizumab, quality of life, and severe eosinophilic asthma.
od: Pavord, I
Izdano: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
od: Howell, I, et al.
Izdano: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
od: Prazma CM, et al.
Izdano: (2021-06-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
od: Imran Howell, et al.
Izdano: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
od: Terufumi Shimoda, et al.
Izdano: (2017-07-01)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
od: Charlene M. Prazma, et al.
Izdano: (2019-05-01)

Eosinophils in asthma and airway hyperresponsiveness.
od: Brightling, C, et al.
Izdano: (2004)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
od: Rastogi, S, et al.
Izdano: (2017)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
od: Kulkarni, N, et al.
Izdano: (2010)

Non-eosinophilic asthma and the innate immune response.
od: Pavord, I
Izdano: (2007)

Severe eosinophilic asthma: a roadmap to consensus.
od: Buhl, R, et al.
Izdano: (2017)

Mepolizumab in refractory eosinophilic asthma.
od: Pavord, I, et al.
Izdano: (2010)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
od: Luo, J, et al.
Izdano: (2024)

A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels
od: Haughney, J, et al.
Izdano: (2017)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
od: Mi-Kyeong Kim, et al.
Izdano: (2021-03-01)

Eosinophilic bioactivities in severe asthma
od: Tara F. Carr, et al.
Izdano: (2016-01-01)

Non-eosinophilic corticosteroid unresponsive asthma.
od: Pavord, I, et al.
Izdano: (1999)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
od: Shrimanker, R, et al.
Izdano: (2017)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
od: Pavord, I, et al.
Izdano: (2019)

Eosinophils in asthma and other allergic diseases.
od: Wardlaw, A, et al.
Izdano: (2000)

The significance of eosinophilic airway inflammation in asthma
od: Pavord, I, et al.
Izdano: (2002)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
od: Brightling, C, et al.
Izdano: (2003)

Asthma heterogeneity and severity
od: Tara F. Carr, et al.
Izdano: (2016-01-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
od: Pavord, I, et al.
Izdano: (2017)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
od: Frank C. Albers, et al.
Izdano: (2019-07-01)

Eosinophils in COPD: just another biomarker?
od: Bafadhel, M, et al.
Izdano: (2017)

Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants.
od: Anees, W, et al.
Izdano: (2002)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
od: Moran, AM, et al.
Izdano: (2020)

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
od: Lavoie, G, et al.
Izdano: (2024)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
od: Shrimanker, R, et al.
Izdano: (2017)